Msd Sub Merck Drug Patent Portfolio

Msd Sub Merck owns 12 orange book drugs protected by 60 US patents with Steglatro having the least patent protection, holding only 1 patent. And Janumet Xr with maximum patent protection, holding 12 patents. Given below is the list of Msd Sub Merck's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10772888 Solid pharmaceutical compositions containing an integrase inhibitor 30 Mar, 2032
Active
US8871759 Inhibitors of hepatitis C virus replication 04 May, 2031
Active
US9649311 Solid pharmaceutical compositions containing an integrase inhibitor 21 Apr, 2031
Active
US9649311 Solid pharmaceutical compositions containing an integrase inhibitor 21 Oct, 2030
Active
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
Active
US9439902 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
Active
US9439901 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
Active
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
Active
US8771733 Pharmaceutical composition containing an anti-nucleating agent 02 Jun, 2030
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
Active
US7973040 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors 24 Jul, 2029
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
Active
US8414921 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jan, 2029
Active
US8414921 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jul, 2028
Active
US8450372 Formulations of suberoylanilide hydroxamic acid and methods for producing same 18 Mar, 2028
Active
US8852632 Pharmaceutical formulation containing a release rate controlling composition 28 Jan, 2028
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
Active
US7456219 Polymorphs of suberoylanilide hydroxamic acid 11 Mar, 2027
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
Active
US8093295 Formulations of suberoylanilide hydroxamic acid and methods for producing the same 16 May, 2026
Active
USRE44733 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block 27 Jan, 2026
Active
US7399787 Methods of treating cancer with HDAC inhibitors 09 Feb, 2025
Active
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024 Expired
US7851509 Polymorphs of suberoylanilide hydroxamic acid 21 Feb, 2024 Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023 Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023 Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023 Expired
US7652069 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023 Expired
US7732490 Methods of treating cancer 04 Mar, 2023 Expired
US8067472 Methods of treating Hodgkin's and non-Hodgkin's lymphoma 04 Mar, 2023 Expired
US8101663 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023 Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023 Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023 Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022 Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022 Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022 Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022 Expired
US6949527 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block 27 Jan, 2021 Expired
US7265009 HDP-CVD methodology for forming PMD layer 07 Aug, 2020 Expired
US7265099 Use of chemical chelators as reversal agents for drug-induced neuromuscular block 07 Aug, 2020 Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019 Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019 Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019 Expired
US5952323 Carbapenem antibiotic 15 Nov, 2017 Expired
US5952323 Carbapenem antibiotic 15 May, 2017 Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017 Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016 Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016 Expired
US5478820 Antibiotic compounds 21 May, 2016 Expired
US5478820 Antibiotic compounds 21 Nov, 2015 Expired
US5807825 Platelet aggregation inhibitors 15 Sep, 2015 Expired
US5968902 Platelet aggregation inhibitors 02 Jun, 2015 Expired
US5747447 Stable polypeptide composition 05 May, 2015 Expired
US5686570 Platelet aggregation inhibitors 11 Nov, 2014 Expired
US5756451 Platelet aggregation inhibitors 11 Nov, 2014 Expired
USRE38506 Potent inducers of terminal differentiation and methods of use thereof 29 Nov, 2013 Expired
US5652233 Antibiotic compounds 02 Aug, 2013 Expired
US7342005 Antibiotic compounds 02 Aug, 2013 Expired
US5652233 Antibiotic compounds 02 Feb, 2013 Expired
US7342005 Antibiotic compounds 02 Feb, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Msd Sub Merck.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
Court Processing Terminated 17 Apr, 2024 US7326708 (Litigated)
Court Processing Terminated 17 Apr, 2024 US7326708 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 08 Feb, 2024 US10772888
Expire Patent 01 Jan, 2024 US8067472
Review Certificate Mailed 19 Sep, 2023 US7326708 (Litigated)
Review Certificate Mailed 19 Sep, 2023 US7326708 (Litigated)
Review Certificate 06 Sep, 2023 US7326708 (Litigated)
Review Certificate 06 Sep, 2023 US7326708 (Litigated)
Maintenance Fee Reminder Mailed 17 Jul, 2023 US8067472
Payment of Maintenance Fee, 12th Year, Large Entity 14 Jun, 2023 US8093295
Payment of Maintenance Fee, 12th Year, Large Entity 10 May, 2023 US8080580
Payment of Maintenance Fee, 12th Year, Large Entity 10 May, 2023 US8080580


Msd Sub Merck's Drug Patent Litigations

Msd Sub Merck's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 17, 2014, against patent number US6635280. The petitioner Endo Pharmaceutical Inc. et al., challenged the validity of this patent, with Depomed, Inc. as the respondent. Click below to track the latest information on how companies are challenging Msd Sub Merck's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision
(10 May, 2021)
Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision
(10 May, 2021)
Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision
(07 May, 2021)
Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled
(08 Dec, 2020)
Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.
US6340475 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6340475 January, 2014 FWD Entered
(08 Jul, 2015)
Depomed, Inc. Purdue Pharma L.P.
US6635280 January, 2014 FWD Entered
(08 Jul, 2015)
DepoMed, Inc. Purdue Pharma L.P.
US6340475 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.


Msd Sub Merck Drug Patents' Oppositions Filed in EPO

Msd Sub Merck drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 11, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04755691A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16198994A Jan, 2020 Ter Meer Steinmeister & Partner Patentanwälte mbB Granted and Under Opposition
EP16198994A Dec, 2019 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition
EP05852790A Aug, 2017 Georg Kalhammer/Stephan Teipel Patent maintained as amended
EP05852790A Aug, 2017 Ter Meer Steinmeister & Partner Patentanwälte mbB Patent maintained as amended
EP05852839A Aug, 2014 Sölch, Günter Patent maintained as amended
EP03711372A May, 2013 Generics [UK] Limited Revoked
EP05077584A Mar, 2011 APOTEX INC. Revoked
EP04755691A Jun, 2008 Teva Pharmaceutical Industries Ltd. Patent maintained as amended


Msd Sub Merck's Family Patents

Msd Sub Merck drugs have patent protection in a total of 61 countries. It's US patent count contributes only to 16.7% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Msd Sub Merck Drug List

Given below is the complete list of Msd Sub Merck's drugs and the patents protecting them.


1. Bridion

Bridion is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE44733 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block 27 Jan, 2026
(1 year, 3 months from now)
Active
US6949527 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block 27 Jan, 2021
(3 years ago)
Expired
US7265009 HDP-CVD methodology for forming PMD layer 07 Aug, 2020
(4 years ago)
Expired
US7265099 Use of chemical chelators as reversal agents for drug-induced neuromuscular block 07 Aug, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bridion's drug page


2. Integrilin

Integrilin is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5807825 Platelet aggregation inhibitors 15 Sep, 2015
(9 years ago)
Expired
US5968902 Platelet aggregation inhibitors 02 Jun, 2015
(9 years ago)
Expired
US5747447 Stable polypeptide composition 05 May, 2015
(9 years ago)
Expired
US5686570 Platelet aggregation inhibitors 11 Nov, 2014
(9 years ago)
Expired
US5756451 Platelet aggregation inhibitors 11 Nov, 2014
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Integrilin's drug page


3. Invanz

Invanz is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5952323
(Pediatric)
Carbapenem antibiotic 15 Nov, 2017
(6 years ago)
Expired
US5952323 Carbapenem antibiotic 15 May, 2017
(7 years ago)
Expired
US5478820
(Pediatric)
Antibiotic compounds 21 May, 2016
(8 years ago)
Expired
US5478820 Antibiotic compounds 21 Nov, 2015
(8 years ago)
Expired
US5652233
(Pediatric)
Antibiotic compounds 02 Aug, 2013
(11 years ago)
Expired
US7342005
(Pediatric)
Antibiotic compounds 02 Aug, 2013
(11 years ago)
Expired
US5652233 Antibiotic compounds 02 Feb, 2013
(11 years ago)
Expired
US7342005 Antibiotic compounds 02 Feb, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invanz's drug page


4. Isentress

Isentress is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8771733 Pharmaceutical composition containing an anti-nucleating agent 02 Jun, 2030
(5 years from now)
Active
US7754731
(Pediatric)
Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
(4 years from now)
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
(4 years from now)
Active
US8852632 Pharmaceutical formulation containing a release rate controlling composition 28 Jan, 2028
(3 years from now)
Active
US7169780
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024
(6 months ago)
Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023
(1 year, 12 days ago)
Expired
US7217713
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(1 year, 5 months ago)
Expired
US7435734
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(1 year, 5 months ago)
Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(1 year, 11 months ago)
Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(1 year, 11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress's drug page


5. Isentress Hd

Isentress Hd is protected by 12 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10772888 Solid pharmaceutical compositions containing an integrase inhibitor 30 Mar, 2032
(7 years from now)
Active
US9649311
(Pediatric)
Solid pharmaceutical compositions containing an integrase inhibitor 21 Apr, 2031
(6 years from now)
Active
US9649311 Solid pharmaceutical compositions containing an integrase inhibitor 21 Oct, 2030
(6 years from now)
Active
US8771733 Pharmaceutical composition containing an anti-nucleating agent 02 Jun, 2030
(5 years from now)
Active
US7754731
(Pediatric)
Potassium salt of an HIV integrase inhibitor 11 Sep, 2029
(4 years from now)
Active
US7754731 Potassium salt of an HIV integrase inhibitor 11 Mar, 2029
(4 years from now)
Active
US7169780
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Apr, 2024
(6 months ago)
Expired
US7169780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 03 Oct, 2023
(1 year, 12 days ago)
Expired
US7217713
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(1 year, 5 months ago)
Expired
US7435734
(Pediatric)
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Apr, 2023
(1 year, 5 months ago)
Expired
US7217713 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(1 year, 11 months ago)
Expired
US7435734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 21 Oct, 2022
(1 year, 11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress Hd's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Janumet

Janumet is protected by 12 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8414921
(Pediatric)
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jan, 2029
(4 years from now)
Active
US8414921 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 21 Jul, 2028
(3 years from now)
Active
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(2 years from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(2 years from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(1 year, 8 months ago)
Expired
US7125873
(Pediatric)
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(1 year, 8 months ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(2 years ago)
Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(2 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet's drug page


7. Janumet Xr

Janumet Xr is protected by 12 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(2 years from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(2 years from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(1 year, 8 months ago)
Expired
US7125873
(Pediatric)
Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(1 year, 8 months ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(2 years ago)
Expired
US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(2 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 24 Apr, 2017
(7 years ago)
Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016
(8 years ago)
Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode 19 Sep, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet Xr's drug page


8. Segluromet

Segluromet is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(6 years from now)
Active
US9439902 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(6 years from now)
Active
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Segluromet's drug page


9. Steglatro

Steglatro is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglatro's drug page


10. Steglujan

Steglujan is protected by 10 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(6 years from now)
Active
US9439901 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 21 Oct, 2030
(6 years from now)
Active
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives 13 Jul, 2030
(5 years from now)
Active
US7326708
(Pediatric)
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 May, 2027
(2 years from now)
Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor 24 Nov, 2026
(2 years from now)
Active
US6699871
(Pediatric)
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jan, 2023
(1 year, 8 months ago)
Expired
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 26 Jul, 2022
(2 years ago)
Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto 02 Feb, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglujan's drug page


11. Zepatier

Zepatier is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8871759 Inhibitors of hepatitis C virus replication 04 May, 2031
(6 years from now)
Active
US7973040 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors 24 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepatier's drug page


12. Zolinza

Zolinza is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8450372 Formulations of suberoylanilide hydroxamic acid and methods for producing same 18 Mar, 2028
(3 years from now)
Active
US7456219 Polymorphs of suberoylanilide hydroxamic acid 11 Mar, 2027
(2 years from now)
Active
US8093295 Formulations of suberoylanilide hydroxamic acid and methods for producing the same 16 May, 2026
(1 year, 6 months from now)
Active
US7399787 Methods of treating cancer with HDAC inhibitors 09 Feb, 2025
(3 months from now)
Active
US7851509 Polymorphs of suberoylanilide hydroxamic acid 21 Feb, 2024
(7 months ago)
Expired
US7652069 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023
(1 year, 7 months ago)
Expired
US7732490 Methods of treating cancer 04 Mar, 2023
(1 year, 7 months ago)
Expired
US8067472 Methods of treating Hodgkin's and non-Hodgkin's lymphoma 04 Mar, 2023
(1 year, 7 months ago)
Expired
US8101663 Polymorphs of suberoylanilide hydroxamic acid 04 Mar, 2023
(1 year, 7 months ago)
Expired
USRE38506 Potent inducers of terminal differentiation and methods of use thereof 29 Nov, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zolinza's drug page